Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter results were weak as it missed estimates for both earnings and sales ...

is arguably the best known and most effective gene editing tool - and CRISPR Therapeutics, alongside partner Vertex Pharmaceuticals Incorporated (VRTX), the Boston-based Pharma giant, secured a ...

Vertex Pharmaceuticals is amending its collaboration with CRISPR Therapeutics, paying $900 million now for chance to grab a bigger share of a gene-editing therapy’s profits later---if the ...

was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD). Crispr Therapeutics and Vertex have ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Image Source: Zacks Investment Research CRISPR Therapeutics and partner Vertex Pharmaceuticals’ VRTX CRISPR/Cas9 gene-edited therapy, Casgevy, was approved for two blood disorder indications ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its ...